Pod Insights Motley Fool Hidden Gems Investing Biotech Beat NVIDIA in 2025. Can It Do It Again? About this episode Big pharma and biotech take the earnings stage this week with reports from Eli Lilly (NYSE: LLNY) and Novo Nordisk (NYSE: NVO) leading the lineup. Will they help the industry once again outperform AI champ NVIDIA (NASDAQ: NVDA), as the industry did in 2025? Karl Thiel, Tom King, and Tim Beyers discuss: - Slow rolling chaos at FDA and its effects on drug approvals. - How to think about risk when investing in biotech. - Earnings predictions for Lilly and Novo as well as a review of results from DNA researcher Twist Bioscience (NASDAQ: TWST). Don’t wait! Be sure to get to your local bookstore and pick up a copy of David’s Gardner’s new book — Rule Breaker Investing: How to Pick the Best Stocks of the Future and Build Lasting Wealth. It’s on shelves now; get it before it’s gone! Companies discussed: RGNX, LLY, NVO, TWST Host: Tim Beyers Guests: Karl Thiel, Tom King Producer: Anand Chokkavelu Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We’re committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices
Transcript 0:05 Speaker 00 Is biotech getting unfairly ignored? You're listening to Motley Fool Money.
0:21 Speaker 00 Welcome, fools. I'm your host, Tim Beyers, and with me are two of my longtime rule breakers teammates, Carl Teal and Tom King. Thanks for being here, guys. Yeah, it's great to be here. Good to be here. We're going to preview some biotech earnings. We're also going to check in on one that reported this morning, and we're going to paint a picture of an industry that probably deserves a little bit more love, a little bit more attention. So get your coffee ready because it's biotech time. Let's talk about biotech approvals, Carl, and what's going on at the FDA because it does seem as though things are a little bit, let's call it turbulent.
0:59 Speaker 01 Let me just paint a little quick background here, which is that 2025 was an absolutely tremendous year for the industry. I don't know if many people realize this, but biotech as a whole, the XBI, for instance, outperformed Nvidia in 2025. It was a very strong year after a very, very long bleak period. And so I do think there's actually a lot of enthusiasm continuing into 2026. But I don't, I don't know what it is about me, Tim. I gotta throw cold water on stuff. I just want to sound, you know, there's, there's a few alarm bells or a few flags out there that I think, you know, are interesting and that people need to be aware of. And, and one of them is the, the sort of continuing chaos, I guess, that we're seeing
1:43 Speaker 01 at FDA, for want of a better word.
1:46 Speaker 00 Well, and it does seem as though there is a, there was a warning from one of a former senior executive here. I think this, this man's name is Richard Pazder, who is the former longtime head of the, the oncology division. I've often heard you talk about the JP Morgan Conference, Carl, that how important it is to the biotech industry, but it sounds like he had some spicy things to say at that conference.
2:10 Speaker 01 Yeah, he did. And this is, this is just a couple of weeks ago in, in January, mid-January. I mean, he's not, he wasn't just the head of oncology. He is one of five people who headed up Cedar, the main drug approval division. So kind of, you know, extremely senior position at FDA, one of five people who did that during 2025 because there was so much turnover in the, in the role. And, you know, one of the things that he told the big pharma people at the conference was that he was worried that the firewall of between political appointees and drug reviewers has been breached is, was, was his quote, and that the pharma industry is continuing to underestimate the damage that's already been done. Now, you know,
2:54 Speaker 01 you can certainly dismiss that as the thoughts of a long-serving bureaucrat who doesn't like the changes that he's seen at the industry. But, you know, what he called chaos, and whether that's the results of just turnover, or politics, or anything else going on, it does seem to describe some of the, you know, seemingly contradictory approaches that we're, we've been seeing to regulation recently.
3:19 Speaker 00 I mean, there, what's interesting here is that, and especially when you say that, it makes me wonder that some of the companies we would look at for the biotech side of the scorecard and rule breakers that are dependent upon the FDA for fast approvals of promising drugs that are in clinical trials. And then suddenly, there's, there's a bit of, maybe some extra risk here. So can you talk me through, when he's, when he's talking about that, is he talking about longer approval cycles? Is he talking about inconsistent approvals? Like, what's the risk here for companies that we follow?
4:00 Speaker 01 We can think about it as just trying to read the tea leaves on how the agency is going to regard various submissions. And I think one area, so I think you have these two different sort of themes going. And one is that under Martin Kari, the current commissioner of FDA, he has been very, very forward looking about how he wants to speed approvals, how he wants to make this easier for industry. And that's something that industry is super enthusiastic about. And so that includes everything for, you know, there's been talk about doing less animal testing. There's been talking about having easier standards for rare diseases where you can
4:42 Speaker 01 basically get on the market for, with a single study, as long as you have some confirmatory evidence, which would make that faster and easier. There's been talk about a plausible mechanism pathway, basically where the agency could approve drugs based on limited clinical data. Basically, if the biology makes sense. So, you know, think about it's like if you have a disease that's marked by an enzyme deficiency and you give them the enzyme, that kind of makes sense that that would work. So, you know, that when you have that kind of plausible mechanism, you can take basically less data to support it. These are all things that industry is super excited about. The thing is, there's sort of an operating reality on the ground that seems to be coming out differently than that.
5:27 Speaker 01 And that's where I think there's a lot of confusion right now is because in some ways the FDA actually seems to be raising the bar on rare disease rather than lowering it. And we've seen that come out in a few different ways.
5:37 Speaker 00 Well, let's talk about those. Like, I would love a couple of examples here of where this is, because what we want to understand as investors is, do we need to be more careful about the types of biotech companies we're looking at here? Because what we thought would be a reasonable approval cycle is no longer. So what are some examples of what we're seeing in the industry right now?
6:03 Speaker 01 Yeah, so and you said what types, what types of products or what types of approvals? And I think that's, that's a very good point right there. A lot of controversy seems to come particularly around things that go through the, the sort of the, the CBR, the biologics division, the, so gene therapies and cell therapies, things in that space seem to be particularly unpredictable right now. And so we just saw that this past week, a company called Regenex Bio was expecting approval of a drug on February 8th for a disease called Hunter Syndrome. That's almost certainly not going to happen now.
6:43 Speaker 01 And, and what's interesting is that it's because a different drug, a different gene therapy, had a complication come up in clinical trials that basically they found a tumor that had developed in somebody that had been treated with the drug four years ago. And so they put it on clinical hold to investigate that further. Now that's, and I want to point out, these are bad fatal diseases, right? So you have some, there, there's some tolerance for, for side effects and bad outcomes and stuff with therapies when you're addressing a fatal rare genetic disease, right?
7:22 Speaker 00 Sure.
7:23 Speaker 01 And so this was a benign tumor, but a tumor nonetheless, it developed in somebody who'd been treating four years earlier. Unclear if it's related to the, the gene therapy itself, but certainly a red flag and, and putting it on hold to investigate that is, is called for. That's the, that's the right call. What's weird is that they put another drug that is just about to get approval supposedly on hold because it's similar. There was no evidence of problems in that. It, it uses a somewhat different vector. I mean, all these things use slightly different vectors, even if they're all technically in the same class. It seems to contradict what FDA had been saying previously, which is that they were
8:05 Speaker 01 going to be more tolerant of these fatal rare diseases. And that's not what we're seeing.
8:11 Speaker 00 Last point on this, or last question, I guess I should say, before we move on to our next section here, but does this make you?
8:20 Speaker 00 Raise the bar for what we would consider a reasonable biotech investment and say like, like rule breakers, like, do we need a bit more, a bit more development, like a biotech company that's more mature before they make it to the scorecard? Or does this really not change anything?
8:43 Speaker 01 I think that you have to realistically put extra risk around anything in the gene therapy, cell therapy space.
8:53 Speaker 00 Okay.
8:54 Speaker 01 You know, I mean, we're just seeing that. We've seen it too many times at this point to not recognize that. I still think there are some really, really interesting possibilities in that space, but you know, you have to maybe build in extra timelines for more questions, for things being delayed and stuff like that, unfortunately. On the other hand, you know, we may finally start to see some things get sped up and we can talk about that a little bit, maybe in our next segment.
9:22 Speaker 00 Okay. Tom, any, any thoughts on this? Does it, does it make you more or less interested in, in biotechs to bring to, to the scorecard?
9:30 Speaker 02 You know, I think Carl said it pretty well. I think we've seen the current skepticism around vaccines and mRNA based therapies. So that I think Carl put it pretty well. You just got to, you just got to factor that in into your risks when you consider the sector and those particular subsectors within the biotech industry.
9:51 Speaker 00 All right. Still like biotech? Maybe lengthen your timeline for how long you're going to stay invested in, in these companies. Up next, we're going to do some biotech earnings predictions. Stay tuned. You're listening to Motley Fool Money.
10:14 Speaker 03 Real traders still hear the noise. They just know when to stop listening to it. Find and research opportunities to fit your strategy with Thinkorswim trading platforms from Schwab. Discover features like robust charting, nearly unlimited customization, and built-in risk management technology. Plus, get 24/7 support from real trading specialists. That's Schwab Trading. Learn more at schwab.com/trading.
10:37 Speaker 00 All right, we are back with Carl Thiel and Tom King. I'm Tim Byers, and let's start with some earnings predictions here. We've got some big names that are reporting this week, guys, and I'm going to start with Eli Lilly, ticker LLY. And I'll give you some of the background on this. This is a big company, and they have, like for some others, we're going to get into another one here, but weight loss drugs, oh, boy, that has been a big driver for Lilly. Earnings per share consensus estimate, a range of $6.99 to $7.86. The consensus estimate is $7.48, revenue of $17.85 billion. Roughly,
11:22 Speaker 00 I mean, this is over 30% relative earnings growth year over year. So, big numbers here. Tom, I'll start with you. Are you expecting a beat, a raise, or a miss for Eli Lilly in its upcoming quarter here? They're going to report, I believe, on the 4th, so Wednesday this week. What do you think?
11:44 Speaker 02 I'm going to go with the beat because I think that guidance is always arranged so that it's possible easy to, more likely to beat. So that would be my guess.
11:54 Speaker 00 Yeah, so low bar, set the low bar and leap over it. Carl, I mean, when you look at the Lilly business, I mean, I assume it's way, way bigger than just weight loss drugs. But is this still, like, is this the weight loss trade? Is that what Lilly is?
12:13 Speaker 01 Yeah, it effectively is. And first of all, I just have to say, by the way, I love that you're you're referring to Lilly as a biotech company. That's such a victory for biotech. This is like a century old big pharma company. It's true. I mean, it's like these GLP-1 drugs, they are biotech drugs and they are they are in the driver's seat right now. Yeah, I would put I would put Lilly down for a beat. I think they've beaten in last three or four quarters. I think they're they're in a super strong position right now. The only thing that could I they probably a decent candidate to raise to the only sort of question mark right now is that CVS pharmacies took terzepatide, which is the
12:58 Speaker 01 active ingredient in both Zepbound and Monjaro. They took that off their formulary last summer. And you saw you saw a little bit of a ripple of it in the third quarter. But this fourth quarter is when we're really going to see if that makes a difference or not that because there were some people switching over to semaglutide after that happened. And that could have some impact. But I think they'll be able to drown that out.
13:20 Speaker 00 Okay, fair enough. So we've got two two beats for Eli Lilly. Moving on, we're going to move on to Novo Nordisk, another one, I think, that's in the, you know, the weight loss trade for lack of a better, a better term here. Ticker NVO, they are also reporting on Wednesday, the fourth. So Tom will come back to you and give you some numbers here. So the earnings per share expectations are between 89 and 90 cents a share. That's versus 91 cents in Q4 of last year. So flat to slightly down revenue of 11.96 billion. And there is the possibility of a dividend coming into this quarter. So what do you
14:05 Speaker 00 think? Beat, raise?
14:08 Speaker 00 Or miss, and I will ask you, what do you put the, what do you put the odds for a dividend from Novo Nordisk at coming into this quarter? Do you have, do you have any thoughts on the odds?
14:21 Speaker 02 Well, in terms of the possibility of a miss, I would probably put that a little bit higher than,
14:27 Speaker 00 Okay.
14:28 Speaker 02 than for Eli Lilly. Novo Nordisk has been on the back for a little bit the last couple of years. They've got a new CEO. Things haven't been, they've been having some struggles with various things. So just for that reason, I would rank the possibility of a miss slightly higher. And the same sort of logic applies to the initiation of that dividend. I, I'm guessing that in time, in a time of uncertainty for them, they'd rather hang on to the cash. So I would, I would say that's probably unlikely, but there's probably, there may well be more to it than that.
15:02 Speaker 00 So less than 50% is what I hear you saying?
15:05 Speaker 02 Yeah, sure.
15:06 Speaker 00 Yeah. Okay. Carl, with the, you know, to beat, beat raise or miss, and I'll put the dividend question to you this way. Given that Novo Nordisk has been a little shakier, as Tom points out, is the dividend what you do to stabilize things amongst the investors? Or is it like, let's conserve the cash and go again?
15:27 Speaker 01 Hmm, I think it's, it's, I think they would frame it a little bit differently. They have a new CEO, the first non-Danish CEO in their company's history, who's already signaled that he's going to go big on acquisitions.
15:41 Speaker 00 Oh, boy.
15:41 Speaker 01 Which to me is, is, which also, by the way, I think they need to do that. Like Novo Nordisk has been traditionally very, very shy about doing M and A. And I think this is a good, that would be a good move for them. But it does, that does make the timing of introducing a dividend make a little more questionable to me. So I would lean towards no on that. And then for the earnings, you know, they've already cut guidance twice, I think, in the last year. So, you know, I'm, I'm looking for them to hopefully meet. It'd be great to see them beat. I do think they're kind of due for a relief at some point. But yeah, I'm a sort of a meet or, or maybe, you know, slightly ahead. I'd like to see a lot is riding on, obviously their oral Wegovy launch.
16:24 Speaker 01 And that's very recent, so it's a little hard for it to move the needle too, too much. But it will certainly play into their, into their guidance going forward for the rest of the year. But the, the numbers for oral Wegovy have been strong.
16:38 Speaker 00 So we've got a miss and a maybe a slight beat or meet. Let's move on to Twist Bioscience, which is a company that we've looked at multiple times in Rule Breakers. And Tom, I'm going to come to you because as we're recording, this is Monday morning, we got results. You know, they did provide some preliminary results, ticker TWST on January 12th, and now we have the real results. So let me ask you, were you surprised? Were you delighted? What'd you see?
17:09 Speaker 02 Well, for the quarter, I, you know, it was pretty much what they said it would be. It was 104 million in revenue for the first quarter of 2026, which ended December 31st, 2025, which is pretty much exactly what they had said it would be when they announced their preliminary results on January 12th. Still unprofitable, but getting better. The bigger picture here is more interesting for me, though, the longer term trend in Twist Biosciences. So it's a company that first, you know, crossed my radar, I think, in 2020. Basically, what Twist does is they make DNA for other people. So you're a researcher,
17:55 Speaker 02 you send, hey, you say to Twist, please make me this DNA with this code of nucleotides. And they do that. The researcher then puts it into a cell and sees what it does. So they heavily are dependent on research, the level of research activity. And as we know, and Carl has said early in the show, we've been through what you might call a bit of a biotech winter the last few years. There's been a fair amount of pessimism in industry, lack of investment, and so on. But what impressed me about Twist when I looked over their longer term results is that they've consistently grown revenue through this period of the
18:39 Speaker 02 last, from 2020 through to last year, adding about 60 million in revenue per year. Their rate of cash burn has gone down. It's still, they're still burning through cash, but it's getting a lot less. You know, it's, I would say, from a business perspective, it's doing all the right things. It's maintained its revenue growth. It's reduced its cash consumption. It's getting towards profitability. And you know, the results they released this morning pretty much confirmed that the trend that has played out over the last five years is continuing satisfactorily. So yeah, it's still an interesting company.
19:22 Speaker 02 It's a, it's a lot cheaper than it was at one point in the 2020, 2021 period. It traded at an eye-watering 111 times revenue multiple. It subsequently reached a low of three times revenue in May of 2023. That was, you know, it would probably translate to a 95% loss or so, a certain decline. And now it's at a more reasonable seven times. So, um, yeah, interesting company.
19:52 Speaker 00 So Carl, let me just ask you very quickly on this and then we'll move to our final segment. But because this is a company that's in DNA research, is some of the chaos you talked about at FDA, does it apply to a company like, like Twist? Are they in, caught in that web of, of chaos?
20:12 Speaker 01 Only indirectly, right? I mean, they're not really working with FDA directly. They're working with companies, you know, who are trying to discover new drugs. So they're, they're insulated from it. And yeah, just, you know, tremendous technology. It's a great, great beaten raise quarter. So hopefully they'll continue to have good things happen.
20:32 Speaker 00 There you go. All right. So that's Eli Lilly, ticker LLY, Novo Nordisk, ticker NVO, and Twist Bioscience, which reported this morning a good beaten raise. Up next, we're going to preview tomorrow's show. Thanks for tuning in. You are listening to Motley Fool Money.
20:49 Speaker 04 Get a concise daily market preview from Charles Schwab, including stock updates, US and global economic news, monetary policy decisions, and key results and statistics that may impact your trading. Schwab Market Update is an original podcast from Charles Schwab. Join host Keith Lanceford for this information-packed daily market preview delivered in 10 minutes or less. Listen today at schwab.com/marketupdatepodcast or wherever you get your podcasts.
21:17 Speaker 04 That's schwab.com/marketupdatepodcast.
21:20 Speaker 00 All right, we are back with our final segment here. Just a preview for tomorrow when Emily Flippen, Jason Hall and Lauren Hurst will be talking about AI and gaming. They are going to talk about Project Genie, which if you have not heard of this, is an AI model designed specifically for creating 3D worlds. That sounds interesting. Honestly, a little bit terrifying, but it'll be Emily, Lauren and Jason. So please stay tuned for that. There are also a lot of biotech earnings that are coming this, this week. So please stay tuned for that at the site. We will have coverage every day for all of the stocks you are following in your portfolio. Carl, Tom, thanks for joining me today. Appreciate it.
22:06 Speaker 00 Good chance to talk some more biotech. Please come back to do this again. People on the program may have interests in the stocks they talk about and the Motley Fool may have formal recommendations for or against. So don't buy or sell stocks based solely on what you hear. All personal finance content follows Motley Fool editorial standards and is not approved by advertisers. Advertisements are sponsored content and provided for informational purposes only. To see our full advertising disclosure, please check out our show notes. That's it for today's Motley Fool Money. Thanks for tuning in. Our engineer today is Dan Boyd. Our producer is Anna Chakavale. I'm Tim Beyers. Thanks to Tom King and Carl Teal for being with me today. Fools, we will see you again tomorrow.
22:52 Speaker 00 Thanks again and fool on.
Previous Interview with Droneshield CEO Oleg Vornik Next When AI Starts Building the Game Page updated November 16, 2026 · transcript and summary are machine-generated